

1 Review

2 Optimal Nutritional Status for a Well-Functioning 3 Immune System is an Important Factor to Protect 4 Against Viral Infections

5 Philip C. Calder ¹, Anitra C. Carr ², Adrian F. Gombart ³, and Manfred Eggersdorfer ^{4,*}

6 ¹ Faculty of Medicine, University of Southampton and NIHR Southampton Biomedical Research Centre,
7 University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton SO16 6YD;
8 P.C.Calder@soton.ac.uk

9 ² Nutrition in Medicine Research Group, Department of Pathology & Biomedical Science, University of
10 Otago, Christchurch, P.O. Box 4345, Christchurch 8140, New Zealand; anitra.carr@otago.ac.nz

11 ³ Linus Pauling Institute, Department of Biochemistry and Biophysics, Oregon State University, 307 Linus
12 Pauling Science Center, Corvallis, OR 97331, USA; adrian.gombart@oregonstate.edu

13 ⁴ University Medical Center Groningen, Department Internal Medicine, 9713 GZ Groningen, The
14 Netherlands.

15 * Correspondence: m.eggersdorfer@bluewin.ch;

16 Received: date; Accepted: date; Published: date

17 **Abstract:** Public health practices including handwashing and vaccinations help reduce the spread
18 and impact of infections. Nevertheless, the global burden of infection is high, and additional
19 measures are necessary. Acute respiratory tract infections, for example, were responsible for more
20 than 2.38 million deaths worldwide in 2016. The role nutrition plays in supporting the immune
21 system is well-established. A wealth of mechanistic and clinical data show that vitamins, including
22 vitamins A, B₆, B₁₂, C, D, E, and folate; trace elements, including zinc, iron, selenium, magnesium,
23 and copper; and the omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid play
24 important and complementary roles in supporting the immune system. Inadequate intake and
25 status of these nutrients are widespread, leading to a decrease in resistance to infections and as a
26 consequence an increase in disease burden. Against this background the following conclusions are
27 made: 1) Supplementation with the above micronutrients and omega-3 fatty acids is a safe, effective,
28 and low-cost strategy to help support optimal immune function; 2) Supplementation above the
29 RDA, but within recommended upper safety limits, for specific nutrients such as vitamins C and D
30 is warranted; and 3) Public health officials are encouraged to include nutritional strategies in their
31 recommendations to improve public health.

32 **Keywords:** immune system; viral infection; influenza; COVID-19; micronutrients; vitamins; omega-
33 3 fatty acids; minerals; vitamin C; vitamin D

35 1. Introduction

36 Acute respiratory tract infections are a major cause of morbidity and mortality across the globe,
37 as illustrated by both seasonal influenza epidemics, and the recent outbreak of the coronavirus
38 disease, COVID-19 caused by SARS-CoV-2 infection. The WHO estimates that worldwide, seasonal
39 influenza alone results in 3 – 5 million cases of severe illness that require hospitalization, and 290,000
40 – 650,000 deaths annually [1]. In aggregate, acute respiratory tract illnesses were estimated to be
41 responsible for more than 2.38 million deaths worldwide in 2016 [2,3]. Indeed, severe lower
42 respiratory tract infections were the most common cause of sepsis-related death globally from 1990 –
43 2017 [4].

44 A number of standard public health practices have been developed to help limit the spread and
45 impact of respiratory viruses, such as regular hand washing, avoiding those showing symptoms of
46 infection, and covering coughs [5]. For certain viruses, such as influenza, annual vaccination
47 campaigns designed to prime the immune response in case of exposure exist in many countries.
48 Influenza is caused by a single-stranded RNA virus, and as such exhibits high mutation rates and
49 rapid evolution, which may allow these viruses to escape from pre-existing neutralizing antibodies
50 in the host [6]. Vaccination programs therefore must make predictions each year as to which strains
51 to vaccinate against, with varying degrees of success. In the US, the Centers for Disease Control and
52 Prevention estimate the current year influenza vaccine to be 45% effective for preventing medically
53 attended, laboratory-confirmed influenza virus. This is consistent with estimates from the previous
54 years when the influenza vaccines were antigenically matched to the circulating viruses [7]. Since the
55 2011 – 2012 season, vaccine efficacy has ranged from 19 – 54% [8].

56 The immune system is comprised of both the innate (fast, non-antigen specific) and adaptive
57 (slower, antigen-specific) responses. The innate immune system is comprised of physical barriers that
58 help prevent pathogen entry (e.g. skin, gut epithelium), antimicrobial peptides, the complement
59 system, and a variety of phagocytic and other cells (e.g. neutrophils, macrophages, natural killer
60 cells), that recognize the presence of pathogens via the expression of nonspecific pattern-recognition
61 receptors [9]. The innate system moves quickly to recognize and destroy “non-self” threats, typically
62 via inflammatory processes, and then resolve the inflammation and repair the damage caused by
63 these events [9]. However, innate immunity does not increase efficacy or speed of response with
64 repeated exposure to a pathogen. Subsequent to the innate response, the adaptive response is
65 engaged. The adaptive response includes antigen-specific cells, e.g. T lymphocytes, subsets of which
66 coordinate the overall adaptive response or kill virally-infected cells, and B lymphocytes, which can
67 be activated to secrete antibodies specific to the infecting pathogen [9]. While slower to respond than
68 the innate system, the adaptive system is responsible for generating immunological “memory”,
69 whereby a repeated infection with the same pathogen will generate a vigorous, fast antigen-specific
70 response [9]. The induction of immunological memory is the mechanism by which vaccines can
71 provide protection against subsequent pathogen exposure.

72 Undoubtedly, public hygiene practices and, when available, vaccinations can be effective
73 mechanisms to provide protection against infectious disease. However, vaccines can take years to
74 create, are not available against all viruses (including the current coronavirus SARS-CoV-2), and
75 provide varying levels of protection. The morbidity and mortality numbers cited above highlight the
76 need for additional strategies to support the immune system, in order to reduce the impact of
77 respiratory and other infections.

78 2. Nutritional Impact on Immunity

79 Often missing in public health discussions around immunity and infection are nutritional
80 strategies to support optimal function of the immune system. This is surprising, given that the
81 importance that nutrition plays in immune function is well established. Several vitamins, including
82 vitamins A, B₆, B₁₂, C, D, E, and folate; and trace elements, including zinc, iron, selenium, magnesium,
83 and copper, play important and complementary roles in supporting both the innate and adaptive
84 immune systems. Deficiencies or suboptimal status in micronutrients negatively affect immune
85 function and can decrease resistance to infections [10–12]. Indeed, with the exceptions of vitamin E
86 and magnesium, each of these micronutrients has been granted health claims in the European Union
87 for contributing to the normal function of the immune system [13]. Other nutrients such as omega-3
88 fatty acids also support an effective immune system, specifically by helping to resolve the
89 inflammatory response [14].

90 The mechanistic roles that micronutrients play to optimize immune function have been well-
91 described recently [10,12]. Most micronutrients exhibit pleiotropic roles in supporting immune
92 function. With respect to innate immunity, the vitamins and minerals listed above collectively
93 function to support the development and maintenance of physical barriers; production and activity
94 of antimicrobial proteins; growth, differentiation and motility/chemotaxis of innate cells; phagocytic

95 and killing (e.g. oxidative burst) activities of neutrophils and macrophages; and promotion of and
96 recovery from inflammation (e.g. cytokine production and antioxidant activity). They also support
97 adaptive immunity, via lymphocyte differentiation, proliferation and homing; cytokine production;
98 antibody production; and the generation of memory cells. The roles that vitamins C and D play in
99 immunity are particularly well elucidated. Vitamin C affects several aspects of immunity, including
100 supporting epithelial barrier function, growth and function of both innate and adaptive immune cells,
101 white blood cell migration to sites of infection, phagocytosis and microbial killing, and antibody
102 production [10]. Many immune cells have vitamin D receptors that affect their function after ligand
103 binding, and as such vitamin D profoundly influences immunity. For example, it promotes
104 differentiation of monocytes to macrophages and increases their killing capacity; modulates the
105 production of inflammatory cytokines; and supports antigen presentation. Furthermore, vitamin D
106 metabolites appear to regulate production of specific antimicrobial proteins that directly kill
107 pathogens, and thus are likely to help reduce infection including in the lungs [15,16].

108 As mentioned above, inflammation is a key component of the immune response. This response
109 is caused by a variety of pro-inflammatory mediators, produced by several different types of cells,
110 resulting in the influx of fluid, immune cells, and other mediators that function to eliminate the
111 infection. Inflammation typically resolves quickly at the end of the immune response, due to
112 activation of specific negative-feedback mechanisms. Among these, the omega-3 fatty acids EPA and
113 DHA present at the site of inflammation are enzymatically converted to specialized pro-resolving
114 mediators (SPMs) known as resolvins, protectins, and maresins. These molecules, along with others,
115 function together to orchestrate the resolution of inflammation and to support healing, including in
116 the respiratory tract [14,17]. Notably, nutritional deficiencies in these essential fatty acids can result
117 in delayed or suboptimal resolution of inflammation [17]. This could be very important in the context
118 of severe COVID-19 which manifests as uncontrolled inflammation, the so-called cytokine storm
119 [18,19], linked with acute respiratory distress syndrome (ARDS). A number of the SPMs formed from
120 EPA and DHA have been shown in animal models to both protect against and resolve acute lung
121 injury and ARDS [20–24]. Nutritional formulas containing antioxidants and rich in EPA and DHA
122 have been used in several human trials of patients with ARDS. A recent Cochrane review of these
123 trials identified a significant improvement in blood oxygenation and significant reductions in
124 ventilation requirement, new organ failures, length of stay in the intensive care unit and mortality at
125 28 days [25]. Taken together these findings suggest an important role for EPA and DHA in
126 ameliorating inflammation and lung injury, perhaps acting via conversion to SPMs.

127 It is not surprising, then, that deficiencies and even suboptimal status of these nutrients can
128 impair immune functions. Depending on the deficient nutrient or nutrients, there can be decreases in
129 the numbers of lymphocytes, impairment of phagocytosis and microbial killing by innate immune
130 cells, altered production of cytokines, reduced antibody responses, and even impairments in wound
131 healing [12]. These functional impairments are, presumably, what lead to the clinical immune-related
132 manifestations of deficiency. Indeed, people deficient in vitamin C are susceptible to severe
133 respiratory infections such as pneumonia [10,26]. A recent meta-analysis reported a significant
134 reduction in the risk of pneumonia with vitamin C supplementation, particularly in individuals with
135 low dietary intakes [27]. In older patients, disease severity and risk of death were reduced with
136 supplementation, particularly in the case where initial plasma levels of vitamin C were low [27].
137 Vitamin C supplementation has also been shown to decrease the duration and severity of upper
138 respiratory tract infections, such as the common cold, and significantly decrease the risk of infection
139 when given prophylactically in people under enhanced physical stress [26,28].

140 Likewise, vitamin D deficiency increases the risk for respiratory infection. Observational studies
141 report an association between low blood concentrations of 25-hydroxyvitamin D (the major vitamin
142 D metabolite) and susceptibility to acute respiratory tract infections [29,30]. Consistent with these
143 findings, several recent meta-analyses have concluded that vitamin D supplementation can reduce
144 the risk of respiratory tract infections in both children and adults [11,31–35]. In 2017, Martineau and
145 colleagues performed a systematic review and meta-analysis of individual participant data (n=10,933)
146 from 25 randomized, double blind, placebo controlled trials of vitamin D supplementation with a

147 specified outcome of acute respiratory tract infection (ARI). They found a 12% reduction for
148 experiencing at least one ARI irrespective of dosing schedule [11]. They found a 19% reduction in
149 individuals taking a daily or weekly dose without bolus doses and no benefit with bolus dosing.
150 Among those receiving a daily or weekly dose, they observed a 25% reduction for those with baseline
151 25(OH)D levels ≥ 25 nmol/L (12 ng/ml) and a 70% reduction for those with baseline levels < 25 nmol/L
152 [23]. They concluded that vitamin D supplementation protected against ARI overall and that it was
153 safe.

154 Clinical outcomes also demonstrate a role for vitamin E in respiratory tract infections. In a
155 randomized controlled trial of 617 nursing home residents, daily supplementation for one year with
156 200 IU vitamin E reduced the risk of upper respiratory tract infections, but not lower respiratory tract
157 infections [36]. Vitamin E enhances T cell-mediated immune function in the face of age-related decline
158 [37]. In one study, supplementation of older adults with vitamin E improved natural killer cell
159 activity, neutrophil chemotaxis and phagocytosis, and mitogen-induced lymphocyte proliferation
160 [38]. In a second study, vitamin E supplementation improved T cell-mediated immunity as measured
161 by increased production of antibodies to hepatitis B virus and tetanus vaccines [39].

162 Finally, marginal zinc deficiency can also impact immunity. Zinc is important for maintenance
163 and development of immune cells for the innate and adaptive immune system. Zinc deficiency results
164 in impaired formation, activation and maturation of lymphocytes, and it disturbs the intercellular
165 communication via cytokines and weakens the innate host defense [40,41]. Those deficient in zinc,
166 particularly children, are prone to increased diarrheal and respiratory morbidity [42,43].

167 Furthermore, data from animal models and epidemiological studies in people indicate that
168 deficiency in specific nutrients, particularly selenium and vitamin E, can lead to reproducible genetic
169 mutations and increased virulence of certain viruses, including coxsackievirus, poliovirus, and
170 murine influenza [44,45]. In a double-blind placebo controlled study, an increase of selenium intake
171 of otherwise healthy subjects with relatively low levels of plasma selenium concentrations improved
172 cellular immunity. Subjects receiving selenium cleared an oral live attenuated poliomyelitis vaccine
173 more rapidly and sequence analysis of the viral genome showed lower numbers of mutations as
174 compared to those receiving the placebo. These data suggest that suboptimal nutrient status in the
175 host population could lead to the emergence of more pathogenic strains of viral diseases, thereby
176 increasing the risks and burdens associated with these illnesses. Given the current situation, it may
177 be beneficial to further pursue this line of investigation.

178 Optimal intake of all these nutrients ideally would be achieved through the consumption of a
179 well-balanced and diverse diet, but this can be difficult to accomplish for the general population.
180 Indeed, it is generally accepted that nutrient inadequacies and deficiencies are widespread [46–50]
181 (and references therein). Biochemical markers of nutrient status are particularly useful in assessing
182 inadequacy or deficiency, and lead to the conclusion that intakes often are not sufficient. For
183 example, extensive data have been published, using blood 25-hydroxyvitamin D levels to assess
184 vitamin D status. A systematic review involving 195 studies in forty-four countries reported that
185 37.3% of the studies found mean values lower than 50 nmol/L [51]. The US IOM committee that
186 reviewed DRIs for vitamin D has suggested that those with concentrations less than this level are at
187 risk for inadequacy, while those with concentrations between 50 – 75 nmol/L are considered sufficient
188 [52,53]. Interestingly, while the highest vitamin D levels were reported in North America, data from
189 the United States still indicate that 8% of the non-infant population was at risk for vitamin D
190 deficiency, and 17% exhibited concentrations below the 25(OH)D level that is associated with
191 desirable intake [53]. Other studies based on 25(OH)D levels indicate that vitamin D inadequacy or
192 deficiency are also prevalent in Europe and China [54–56]. Similarly, a recent systematic review
193 involving 132 studies of serum alpha-tocopherol status indicated that 13% of the values were below
194 the threshold of deficiency (12 μ mol/L). Deficiency was noted in the Americas, Asia Pacific, Europe,
195 the Middle East and Africa [57]. The situation with vitamin C is similar. Currently, the most
196 commonly used vitamin C cutoff levels are approximately ≤ 23 –28 μ mol/L for hypovitaminosis C and
197 ≤ 11 μ mol/L for deficiency [58]. The evidence indicates that vitamin C insufficiency or deficiency is
198 common in low and middle-income countries (e.g. Mexico, Brazil, India), and not uncommon in high

199 income countries (e.g. US, Singapore, New Zealand), particularly in at-risk subpopulations [53,59–
 200 67]. Furthermore, the WHO and FAO have described that, based on blood markers, vitamin A and
 201 iron deficiencies are widespread and of significant global concern [46,49,50]. Status data in the general
 202 population or specific subpopulations also reveal inadequacies or deficiencies in various countries,
 203 including in developed nations, for vitamins B6, B12, and folate, as well as zinc and selenium
 204 [53,59,60,68–73]. Finally, a global survey of EPA + DHA status in the blood, from 298 studies, found
 205 “low” or “very low” status (i.e. levels associated with increased risk of cardiovascular related
 206 mortality) of EPA + DHA in most of the countries assessed [74]. Collectively, the totality of these data
 207 strongly suggest that micronutrient and omega-3 inadequacies or deficiencies are prevalent around
 208 the globe.

209 It should also be noted that optimal nutritional support for the immune system can require
 210 intakes above the RDA for some micronutrients, while at the same time infections and other stressors
 211 can reduce micronutrient status in the body. Vitamin C levels, in particular, decrease during times of
 212 infection and higher intakes are required to restore normal blood levels [10,75]. These higher intakes
 213 and blood levels are associated with improved clinical outcomes. For example, supplementation of
 214 pneumonia patients with ≥ 200 mg/d vitamin C restored depleted plasma and cellular vitamin C
 215 levels, and resulted in decreased respiratory symptom scores and a dose-dependent decrease in
 216 hospital length of stay [76,77].

217 3. Recommendations and Conclusions

218 Thus, a set of clear nutritional recommendations is needed (Table 1). First, supplementation with
 219 micronutrients and omega-3 fatty acids is a safe, effective, and low-cost way to help eliminate
 220 nutritional gaps and support optimal immune function, and therefore reduce the risk and
 221 consequences of infections [10,12]. Intakes should follow recommended upper safety limits set by
 222 expert authorities, such as the European Food Safety Authority and, in the United States, the Institute
 223 of Medicine. Thus, a multivitamin and mineral supplement that supplies the basic micronutrient
 224 requirements (e.g. RDA) for vitamins and minerals is recommended in addition to the consumption
 225 of a well-balanced diet.

226 **Table 1.** Recommended intakes of selected nutrients to support optimal immune function.

Nutrient	Rationale	Recommendation
Vitamins and trace elements	These micronutrients play important roles in supporting the cells and tissues of the immune system. Deficiencies or suboptimal status in these micronutrients negatively affect immune function and can decrease resistance to infections.	A multivitamin & trace element supplement that supplies the nutrient requirements (e.g. 100% US RDA for age and gender) [83] for vitamins and trace elements including vitamins A, B ₆ , B ₁₂ , C, D, E, and folate, and trace elements including zinc, iron, selenium, magnesium and copper. This is in addition to the consumption of a well-balanced diet.
Vitamin C	Doses of ≥ 200 mg/day provide saturating levels in the blood, and support reduction in the risk, severity and duration of upper and lower respiratory tract infections. Requirements for vitamin C increase during infection.	Daily intake of at least 200 mg/day for healthy individuals. In individuals who are sick, 1-2 g/day is recommended.
Vitamin D	Daily supplementation of vitamin D reduces the risk of upper respiratory tract infections.	Daily intake of 2000 IU/day (50 μ g/day).

Zinc	Marginal zinc deficiency can impact immunity. Those deficient in zinc, particularly children, are prone to increased diarrheal and respiratory morbidity.	Daily intake in the range of 8-11 mg/day.
Omega-3 fatty acids (EPA + DHA)	Omega-3 fatty acids support an effective immune system, including by helping to resolve inflammation.	Daily intake of 250 mg/day of EPA + DHA.

227 Second, we recommend supplementation above the RDA for vitamins C and D. As noted above,
 228 recent meta-analyses concluded significant reductions in the risk and impact of both upper and lower
 229 respiratory tract infections such as the common cold and pneumonia, including disease severity and
 230 risk of death in older patients, with vitamin C supplementation [27,28,78]. Based on this evidence, a
 231 daily intake of at least 200 mg/day for healthy individuals is recommended. This level is above the
 232 US RDA of 75 and 90 mg/day for female and male adults, respectively [79]. It should be noted that
 233 vitamin C requirements depend on health status, and 1 – 2 g/day are recommended to restore normal
 234 blood levels in individuals who are sick, beginning at the onset of symptoms. These levels are within
 235 the US Tolerable Upper Limit (TUL) for adults of 2 g/day (note that the upper limit for children aged
 236 1 - 3 years is 400 mg/day) [79].

237 Several recent meta-analyses have concluded that vitamin D supplementation reduces the risk
 238 of respiratory tract infections in both children and adults [11,31–35]. Protective effects were seen
 239 with those receiving daily or weekly vitamin D, but not with less frequent bolus doses [11,32]. A
 240 daily intake of 2000 IU (50 µg) is recommended. This is above the US RDA of 400 – 800 IU
 241 (depending on age), but below the TUL for those over 1 year of age (2,500 – 4000 IU) [52].

242 A third recommendation involves the omega-3 fatty acids EPA and DHA. An adequate intake
 243 supports the resolution of inflammation via the production of anti-inflammatory metabolites of these
 244 fatty acids, including in the respiratory tract [14,17]. An intake of 250 mg EPA + DHA per day is
 245 recommended, consistent with global, regional and national expert recommendations [80–82].

246 Public health practices, such as vaccinations and hygiene measures, are important measures that
 247 help limit the spread and impact of infections, including against acute respiratory viruses. However,
 248 the present situation with SARS-CoV-2 infection and severe outcomes of COVID-19 and the annual
 249 morbidity and mortality figures for respiratory infections overall make it clear that these practices
 250 alone are not sufficient. New strains of influenza continuously emerge, necessitating development of
 251 new vaccines with varying efficacy, and outbreaks of novel viruses can be enormously difficult to
 252 contain. As such, additional safe and cost-effective strategies are needed to support the immune
 253 system, and further protect individuals and populations from harm. One compelling strategy is to
 254 provide sufficient nutritional support for the immune system. As described above, optimal nutrient
 255 intake, including supplementing above the RDA for certain immune-supporting vitamins, promotes
 256 optimal immune function, helps to control the impact of infections, and could help limit the
 257 emergence of novel, more virulent strains of pathogenic viruses. We therefore strongly encourage
 258 public health officials to also include nutritional strategies in their arsenal to improve public health
 259 and to limit the impact of seasonal and emerging viral infections.

260

261 **Author Contributions:** The outline of the publication was developed with input from all authors based on an
 262 expert webinar meeting they held and the conclusions they reached concerning the role of the immune system
 263 to reduce risk for infections including viral infections; all authors reviewed the manuscript and approved it.

264 **Funding:** This research received no external funding.

265 **Conflicts of Interest:** PCC has research funding from BASF AS and Bayer Consumer Care; acts as an
 266 advisor/consultant to BASF AS, DSM, Cargill, Smartfish, Nutrileads, Bayer Consumer Care, and Pfizer (now
 267 GSK) Consumer Healthcare; has received reimbursement for travel and/or speaking from Danone, Fresenius
 268 Kabi, Baxter, Pfizer (now GSK) Consumer Healthcare, Abbott, Smartfish, Biogredia and the California Walnut

269 Commission; and is President and member of the Board of Directors of the European Branch of the International
270 Life Sciences Institute. AC has received research funding from Bayer Consumer Care and travel reimbursement
271 from DSM. ME acts as an advisor for DSM and received travel reimbursement from DSM. He is member of the
272 Scientific Board of PM International and President of the Gesellschaft für angewandte Vitaminforschung. AFG
273 has received research funding from Bayer Consumer Care and has acted as an advisor/consultant for and has
274 received reimbursement for travel and/or speaking from Bayer Consumer Care.
275
276

277 **References**

- 278 1. World Health Organization Influenza (Seasonal). Available online: [https://www.who.int/news-](https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal))
279 [room/fact-sheets/detail/influenza-\(seasonal\)](https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)) (accessed on Mar 2, 2020).
- 280 2. Naghavi, M.; Abajobir, A.A.; Abbafati, C.; Abbas, K.M.; Abd-Allah, F.; Abera, S.F.; Aboyans, V.;
281 Adetokunboh, O.; Afshin, A.; Agrawal, A.; et al. Global, regional, and national age-sex specific
282 mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of
283 Disease Study 2016. *Lancet* **2017**, *390*, 1151–1210.
- 284 3. Troeger, C.; Blacker, B.; Khalil, I.A.; Rao, P.C.; Cao, J.; Zimsen, S.R.M.; Albertson, S.B.;
285 Deshpande, A.; Farag, T.; Abebe, Z.; et al. Estimates of the global, regional, and national
286 morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016:
287 a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Infect Dis* **2018**, *18*, 1191–
288 1210.
- 289 4. Rudd, K.E.; Johnson, S.C.; Agesa, K.M.; Shackelford, K.A.; Tsoi, D.; Kievlan, D.R.; Colombara,
290 D.V.; Ikuta, K.S.; Kissoon, N.; Finfer, S.; et al. Global, regional, and national sepsis incidence and
291 mortality, 1990–2017: analysis for the Global Burden of Disease Study. *Lancet* **2020**, *395*, 200–211.
- 292 5. U.S. Centers for Disease Control Take 3 Actions to Fight Flu. Available online:
293 <https://www.cdc.gov/flu/prevent/preventing.htm> (accessed on Mar 2, 2020).
- 294 6. Visher, E.; Whitefield, S.E.; McCrone, J.T.; Fitzsimmons, W.; Lauring, A.S. The mutational
295 robustness of Influenza A virus. *PLoS Pathog* **2016**, *12*, e1005856.
- 296 7. Dawood, F.S.; Chung, J.R.; Kim, S.S.; Zimmerman, R.K.; Nowalk, M.P.; Jackson, M.L.; Jackson,
297 L.A.; Monto, A.S.; Martin, E.T.; Belongia, E.A.; et al. Interim estimates of 2019–20 seasonal
298 influenza vaccine effectiveness — United States, February 2020. *MMWR Morb Mortal Wkly Rep*
299 **2020**, *69*, 177–182.
- 300 8. U.S. Centers for Disease Control Seasonal Influenza Vaccine Effectiveness, 2018–2019. Available
301 online: <https://www.cdc.gov/flu/vaccines-work/2018-2019.html> (accessed on Mar 2, 2020).
- 302 9. Murphy, K.; Weaver, C. *Janeway's Immunobiology*, 9th ed.; Taylor & Francis, USA, 2017; pp. 1–35.
- 303 10. Carr, A.C.; Maggini, S. Vitamin C and immune function. *Nutrients* **2017**, *9*, 1211.
- 304 11. Martineau, A.R.; Jolliffe, D.A.; Hooper, R.L.; Greenberg, L.; Aloia, J.F.; Bergman, P.; Dubnov-Raz,
305 G.; Esposito, S.; Ganmaa, D.; Ginde, A.A.; et al. Vitamin D supplementation to prevent acute
306 respiratory tract infections: systematic review and meta-analysis of individual participant data.
307 *BMJ* **2017**, *356*.
- 308 12. Gombart, A.F.; Pierre, A.; Maggini, S. A review of micronutrients and the immune system–
309 working in harmony to reduce the risk of infection. *Nutrients* **2020**, *12*, 236.
- 310 13. EU register on nutrition and health claims. Available online:
311 https://ec.europa.eu/food/safety/labelling_nutrition/claims/register/public/?event=search
312 (accessed on Mar 5, 2020).
- 313 14. Calder, P.C. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or
314 pharmacology?: omega-3 fatty acids and inflammation. *Br J Clin Pharmacol* **2012**, *75*, 645–662.
- 315 15. Gombart, A.F. The vitamin D–antimicrobial peptide pathway and its role in protection against
316 infection. *Future Microbiol* **2009**, *4*, 1151.
- 317 16. Greiller, C.; Martineau, A. Modulation of the immune response to respiratory viruses by vitamin
318 D. *Nutrients* **2015**, *7*, 4240–4270.

- 319 17. Basil, M.C.; Levy, B.D. Specialized pro-resolving mediators: endogenous regulators of infection
320 and inflammation. *Nat Rev Immunol* **2016**, *16*, 51–67.
- 321 18. Mehta, P.; McAuley, D.F.; Brown, M.; Sanchez, E.; Tattersall, R.S.; Manson, J.J. COVID-19:
322 consider cytokine storm syndromes and immunosuppression. *Lancet* **2020**, *395*, 1033–1034.
- 323 19. Pedersen, S.F.; Ho, Y.-C. SARS-CoV-2: A Storm is Raging. *J Clin Invest* **2020**,
324 <https://doi.org/10.1172/JCI137647>.
- 325 20. Gao, Y.; Zhang, H.; Luo, L.; Lin, J.; Li, D.; Zheng, S.; Huang, H.; Yan, S.; Yang, J.; Hao, Y.; et al.
326 Resolvin D1 improves the resolution of inflammation via activating NF- κ B p50/p50-mediated
327 cyclooxygenase-2 expression in acute respiratory distress syndrome. *J Immunol* **2017**, *199*, 2043–
328 2054.
- 329 21. Wang, Q.; Yan, S.-F.; Hao, Y.; Jin, S.-W. Specialized pro-resolving mediators regulate alveolar
330 fluid clearance during acute respiratory distress syndrome: *Chin Med J* **2018**, *131*, 982–989.
- 331 22. Sham, H.P.; Walker, K.H.; Abdulnour, R.-E.E.; Krishnamoorthy, N.; Douda, D.N.; Norris, P.C.;
332 Barkas, I.; Benito-Figueroa, S.; Colby, J.K.; Serhan, C.N.; et al. 15-epi-Lipoxin A₄, Resolvin D2,
333 and Resolvin D3 induce NF- κ B regulators in bacterial pneumonia. *J Immunol* **2018**, *200*, 2757–
334 2766.
- 335 23. Sekheri, M.; El Kebir, D.; Edner, N.; Filep, J.G. 15-Epi-LXA₄ and 17-epi-RvD1 restore TLR9-
336 mediated impaired neutrophil phagocytosis and accelerate resolution of lung inflammation. *Proc*
337 *Natl Acad Sci USA* **2020**, DOI: 10.1073/pnas.1920193117.
- 338 24. Zhang, H.-W.; Wang, Q.; Mei, H.-X.; Zheng, S.-X.; Ali, A.M.; Wu, Q.-X.; Ye, Y.; Xu, H.-R.; Xiang,
339 S.-Y.; Jin, S.-W. RvD1 ameliorates LPS-induced acute lung injury via the suppression of
340 neutrophil infiltration by reducing CXCL2 expression and release from resident alveolar
341 macrophages. *Int Immunopharmacol* **2019**, *76*, 105877.
- 342 25. Dushianthan, A.; Cusack, R.; Burgess, V.A.; Grocott, M.P.; Calder, P.C. Immunonutrition for
343 acute respiratory distress syndrome (ARDS) in adults. *Cochrane Database Syst Rev* **2019**, Art. No.:
344 CD012041.
- 345 26. Hemilä, H. Vitamin C and infections. *Nutrients* **2017**, *9*, 339.
- 346 27. Hemilä, H.; Louhiala, P. Vitamin C for preventing and treating pneumonia. *Cochrane Database*
347 *Syst Rev* **2013**, DOI: 10.1002/14651858.CD005532.pub3.
- 348 28. Hemilä, H.; Chalker, E. Vitamin C for preventing and treating the common cold. *Cochrane*
349 *Database Syst Rev* **2013**, DOI: 10.1002/14651858.CD000980.pub4.
- 350 29. Cannell, J.J.; Vieth, R.; Umhau, J.C.; Holick, M.F.; Grant, W.B.; Madronich, S.; Garland, C.F.;
351 Giovannucci, E. Epidemic influenza and vitamin D. *Epidemiol. Infect.* **2006**, *134*, 1129–1140.
- 352 30. Jolliffe, D.A.; Griffiths, C.J.; Martineau, A.R. Vitamin D in the prevention of acute respiratory
353 infection: systematic review of clinical studies. *J Steroid Biochem Mol Biol* **2013**, *136*, 321–329.
- 354 31. Autier, P.; Mullie, P.; Macacu, A.; Dragomir, M.; Boniol, M.; Coppens, K.; Pizot, C.; Boniol, M.
355 Effect of vitamin D supplementation on non-skeletal disorders: a systematic review of meta-
356 analyses and randomised trials. *Lancet Diabetes Endocrinol* **2017**, *5*, 986–1004.
- 357 32. Martineau, A.R.; Jolliffe, D.A.; Greenberg, L.; Aloia, J.F.; Bergman, P.; Dubnov-Raz, G.; Esposito,
358 S.; Ganmaa, D.; Ginde, A.A.; Goodall, E.C.; et al. Vitamin D supplementation to prevent acute
359 respiratory infections: individual participant data meta-analysis. *Health Technol Assess* **2019**, *23*,
360 1–44.

- 361 33. Rejnmark, L.; Bislev, L.S.; Cashman, K.D.; Eiríksdóttir, G.; Gaksch, M.; Grübler, M.; Grimnes, G.;
362 Gudnason, V.; Lips, P.; Pilz, S.; et al. Non-skeletal health effects of vitamin D supplementation:
363 A systematic review on findings from meta-analyses summarizing trial data. *PLOS ONE* **2017**,
364 *12*, e0180512.
- 365 34. Bergman, P.; Lindh, Å.U.; Björkhem-Bergman, L.; Lindh, J.D. Vitamin D and respiratory tract
366 infections: a systematic review and meta-analysis of randomized controlled trials. *PLoS ONE*
367 **2013**, *8*, e65835.
- 368 35. Charan, J.; Goyal, J.P.; Saxena, D.; Yadav, P. Vitamin D for prevention of respiratory tract
369 infections: A systematic review and meta-analysis. *J Pharmacol Pharmacother* **2012**, *3*, 300.
- 370 36. Meydani, S.N.; Leka, L.S.; Fine, B.C.; Dallal, G.E.; Keusch, G.T.; Singh, M.F.; Hamer, D.H. Vitamin
371 E and respiratory tract infections in elderly nursing home residents: a randomized controlled
372 trial. *JAMA* **2004**, *292*, 828–836.
- 373 37. Wu, D.; Meydani, S. Age-associated changes in immune function: impact of vitamin E
374 intervention and the underlying mechanisms. *Endocr Metab Immune Disord Drug Targets* **2014**, *14*,
375 283–289.
- 376 38. De la Fuente, M.; Hernanz, A.; Guayerbas, N.; Manuel Victor, V.; Arnalich, F. Vitamin E ingestion
377 improves several immune functions in elderly men and women. *Free Radic Res* **2008**, *42*, 272–280.
- 378 39. Meydani, S.N. Vitamin E supplementation and in vivo immune response in healthy elderly
379 subjects. A randomized controlled trial. *JAMA* **1997**, *277*, 1380–1386.
- 380 40. Gammoh, N.Z.; Rink, L. Zinc in infection and inflammation. *Nutrients* **2017**, *9*, 624.
- 381 41. Maares, M.; Haase, H. Zinc and immunity: an essential interrelation. *Arch Biochem Biophys* **2016**,
382 *611*, 58–65.
- 383 42. Aggarwal, R.; Sentz, J.; Miller, M.A. Role of zinc administration in prevention of childhood
384 diarrhea and respiratory illnesses: a meta-analysis. *Pediatrics* **2007**, *119*, 1120–1130.
- 385 43. Roth, D.E.; Richard, S.A.; Black, R.E. Zinc supplementation for the prevention of acute lower
386 respiratory infection in children in developing countries: meta-analysis and meta-regression of
387 randomized trials. *Int J Epidemiol* **2010**, *39*, 795–808.
- 388 44. Beck, M.A.; Levander, O.A.; Handy, J. Selenium deficiency and viral infection. *J Nutr* **2003**, *133*,
389 1463S-1467S.
- 390 45. Beck, M.; Handy, J.; Levander, O. Host nutritional status: the neglected virulence factor. *Trends*
391 *Microbiol* **2004**, *12*, 417–423.
- 392 46. Food and Agriculture Organization of the United Nations. *Europe and Central Asia Regional*
393 *Overview of Food Insecurity 2016: The Food Insecurity Transition.*; FAO: Budapest, 2017; pp. 1-44.
- 394 47. Maggini, S.; Pierre, A.; Calder, P. Immune function and micronutrient requirements change over
395 the life course. *Nutrients* **2018**, *10*, 1531.
- 396 48. Bailey, R.L.; West Jr., K.P.; Black, R.E. The epidemiology of global micronutrient deficiencies. *Ann*
397 *Nutr Metab* **2015**, *66*, 22–33.
- 398 49. World Health Organization; U.S. Centers for Disease Control and Prevention. *Worldwide*
399 *Prevalence of Anaemia 1993-2005: WHO Global Database of Anaemia*; WHO: Geneva, 2008; pp. 1-41.
- 400 50. World Health Organization. *The World Health Report 2002: Reducing Risks, Promoting Healthy Life*;
401 WHO: Geneva, 2002; pp. 1-248.

- 402 51. Hilger, J.; Friedel, A.; Herr, R.; Rausch, T.; Roos, F.; Wahl, D.A.; Pierroz, D.D.; Weber, P.;
403 Hoffmann, K. A systematic review of vitamin D status in populations worldwide. *Br J Nutr* **2014**,
404 *111*, 23–45.
- 405 52. U.S. Institute of Medicine. *Dietary Reference Intakes for Calcium and Vitamin D*; National Academies
406 Press: Washington, D.C., 2011.
- 407 53. US Centers for Disease Control and Prevention. *Second National Report on Biochemical Indicators of*
408 *Diet and Nutrition in the U.S. Population*; CDC, 2012; pp. 1–484.
- 409 54. Cashman, K.D.; Dowling, K.G.; Skrabakova, Z.; Gonzalez-Gross, M.; Valtuena, J.; De Henauw,
410 S.; Moreno, L.; Damsgaard, C.T.; Michaelsen, K.F.; Molgaard, C.; et al. Vitamin D deficiency in
411 Europe: pandemic? *Am J Clin Nutr* **2016**, *103*, 1033–1044.
- 412 55. Hu, Y.; Chen, J.; Wang, R.; Li, M.; Yun, C.; Li, W.; Yang, Y.; Piao, J.; Yang, X.; Yang, L. Vitamin D
413 nutritional status and its related factors for Chinese children and adolescents in 2010–2012.
414 *Nutrients* **2017**, *9*, 1024.
- 415 56. Yun, C.; Chen, J.; He, Y.; Mao, D.; Wang, R.; Zhang, Y.; Yang, C.; Piao, J.; Yang, X. Vitamin D
416 deficiency prevalence and risk factors among pregnant Chinese women. *Public Health Nutr* **2017**,
417 *20*, 1746–1754.
- 418 57. Peter, S.P., et; Friedel, A.; Roos, F.F.; Wyss, A.; Eggersdorfer, M.; Hoffmann, K.; Weber, P. A
419 systematic review of global alpha-tocopherol status as assessed by nutritional intake levels and
420 blood serum concentrations. *Int J Vitam Nutr Res* **2016**, 261–281.
- 421 58. Lykkesfeldt, J.; Poulsen, H.E. Is vitamin C supplementation beneficial? Lessons learned from
422 randomised controlled trials. *Br J Nutr* **2010**, *103*, 1251–1259.
- 423 59. García, O.; Ronquillo, D.; Caamaño, M. del; Camacho, M.; Long, K.; Rosado, J.L. Zinc, vitamin A,
424 and vitamin C status are associated with leptin concentrations and obesity in Mexican women:
425 results from a cross-sectional study. *Nutr Metab (Lond)* **2012**, *9*, 59.
- 426 60. Villalpando, S.; Montalvo-Velarde, I.; Zambrano, N.; Carcia-Guerra, A.; Ramirez-Silva, C.I.;
427 Shamah-Levy, T.; Rivera, J.A. Vitamin A, and C and folate status in Mexican children under 12
428 years and women 12–49 years: a probabilistic national survey. *Salud Publica Mex* **2003**, *45*, S508–
429 S519.
- 430 61. García, O.; Ronquillo, D.; del Carmen Caamaño, M.; Martínez, G.; Camacho, M.; López, V.;
431 Rosado, J. Zinc, iron and vitamins A, C and E are associated with obesity, inflammation, lipid
432 profile and insulin resistance in Mexican school-aged children. *Nutrients* **2013**, *5*, 5012–5030.
- 433 62. Madruga de Oliveira, A.; Rondó, P.H.C.; Mastroeni, S.S.; Oliveira, J.M. Plasma concentrations of
434 ascorbic acid in parturients from a hospital in Southeast Brazil. *Clin Nutr* **2008**, *27*, 228–232.
- 435 63. Ravindran, R.D.; Vashist, P.; K. Gupta, S.; S. Young, I.; Maraini, G.; Camparini, M.; Jayanthi, R.;
436 John, N.; Fitzpatrick, K.E.; Chakravarthy, U.; et al. Prevalence and risk factors for vitamin C
437 deficiency in north and south India: a two centre population based study in people aged 60 years
438 and over. *PLoS ONE* **2011**, *6*, e28588.
- 439 64. Schleicher, R.L.; Carroll, M.D.; Ford, E.S.; Lacher, D.A. Serum vitamin C and the prevalence of
440 vitamin C deficiency in the United States: 2003–2004 National Health and Nutrition Examination
441 Survey (NHANES). *Am J Clin Nutr* **2009**, *90*, 1252–1263.
- 442 65. Hughes, K.; New, A.L.; Lee, B.L.; Ong, C.N. Plasma vitamins A, C and E in the general population
443 of Singapore, 1993 to 1995. *Ann Acad Med Singapore* **1998**, *27*, 149–153.

- 444 66. Hughes, K.; Ong, C.N. Vitamins, selenium, iron, and coronary heart disease risk in Indians,
445 Malays, and Chinese in Singapore. *J Epidemiol Community Health* **1998**, *52*, 181–185.
- 446 67. Pearson, J.; Pullar, J.; Wilson, R.; Spittlehouse, J.; Vissers, M.; Skidmore, P.; Willis, J.; Cameron,
447 V.; Carr, A. Vitamin C status correlates with markers of metabolic and cognitive health in 50-
448 year-olds: findings of the CHALICE cohort study. *Nutrients* **2017**, *9*, 831.
- 449 68. Bird, J.; Murphy, R.; Ciappio, E.; McBurney, M. Risk of deficiency in multiple concurrent
450 micronutrients in children and adults in the United States. *Nutrients* **2017**, *9*, 655.
- 451 69. Bruins, M.J.; Bird, J.K.; Aebischer, C.P.; Eggersdorfer, M. Considerations for secondary
452 prevention of nutritional deficiencies in high-risk groups in high-income countries. *Nutrients*
453 **2018**, *10*, 47.
- 454 70. Gibson, R.S.; Heath, A.-L.M.; Limbaga, M.L.S.; Prosser, N.; Skeaff, C.M. Are changes in food
455 consumption patterns associated with lower biochemical zinc status among women from
456 Dunedin, New Zealand? *Br J Nutr* **2001**, *86*, 71–80.
- 457 71. Baqui, A.H.; Black, R.E.; Fischer Walker, C.L.; Arifeen, S.; Zaman, K.; Yunus, M.; Wahed, M.A.;
458 Caulfield, L.E. Zinc supplementation and serum zinc during diarrhea. *Indian J Pediatr* **2006**, *73*,
459 493–497.
- 460 72. Combs, Jr., G.F. Biomarkers of selenium status. *Nutrients* **2015**, *7*, 2209–2236.
- 461 73. Stoffaneller, R.; Morse, N. A review of dietary selenium intake and selenium status in Europe
462 and the Middle East. *Nutrients* **2015**, *7*, 1494–1537.
- 463 74. Stark, K.D.; Van Elswyk, M.E.; Higgins, M.R.; Weatherford, C.A.; Salem, N. Global survey of the
464 omega-3 fatty acids, docosahexaenoic acid and eicosapentaenoic acid in the blood stream of
465 healthy adults. *Prog Lipid Res* **2016**, *63*, 132–152.
- 466 75. Carr, A.C. Vitamin C in pneumonia and sepsis. In *Vitamin C: New Biochemical and Functional*
467 *Insights*; Chen, Q; Vissers, M.C.M., Eds.; CRC Press: Boca Raton, FL, USA, 2020; pp. 115–135.
- 468 76. Hunt, C.; Chakravorty, N.K.; Annan, G.; Habibzadeh, N.; Schorah, C.J. The clinical effects of
469 vitamin C supplementation in elderly hospitalised patients with acute respiratory infections.
470 *Internat J Vit Nutr Res* **1994**, *64*, 212–219.
- 471 77. Mochalkin, N.I. Ascorbic acid in the complex treatment of patients with acute pneumonia.
472 *Voенно-Meditsinskii Zhurnal*. **1970**, *9*, 17–21.
- 473 78. Ran, L.; Zhao, W.; Wang, J.; Wang, H.; Zhao, Y.; Tseng, Y.; Bu, H. Extra dose of vitamin C based
474 on a daily supplementation shortens the common cold: a meta-analysis of 9 randomized
475 controlled trials. *Biomed Res Intl*. **2018**, doi.org/10.1155/2018/1837634.
- 476 79. Institute of Medicine. *Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids*;
477 The National Academies Press: Washington, D.C., USA, 2000.
- 478 80. EFSA Panel on Dietetic Products. Scientific opinion on dietary reference values for fats, including
479 saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, trans fatty acids,
480 and cholesterol. *EFSA J* **2010**, *8*, 1461.
- 481 81. Food and Agriculture Organization of the United Nations. Chapter 2: summary of conclusions
482 and dietary recommendations on total fat and fatty acids. In *Fats and fatty acids in human nutrition:*
483 *report of an expert consultation: 10-14 November 2008, Geneva*; Food and Agriculture Organization
484 of the United Nations: Rome, 2010; pp. 9–20.
- 485 82. Chinese Nutrition Society. *Chinese Dietary Reference Intakes Summary (2013)*; People’s Medical
486 Publishing House: Beijing, China, 2013; p. 16.

- 487 83. Institute of Medicine. *Dietary Reference Intakes: The Essential Guide to Nutrient Requirements*; The
488 National Academies Press: Washington, D.C, USA, 2006.
489
490
491